Opus Genetics Secures Funding for MERTK Program

Opus Genetics ( (IRD) ) just unveiled an update.

On June 13, 2025, Opus Genetics entered into a funding agreement with the Foundation Fighting Blindness Retinal Degeneration Fund to support its MERTK Program, aimed at developing gene therapies for retinitis pigmentosa. The agreement provides up to $2 million in nondilutive funding, with $1 million disbursed soon and the remaining contingent on milestone achievements. The company must meet certain development milestones or collaborate with RDF to out-license rights. Additionally, Opus Genetics will make milestone and tiered royalty payments to RDF, with provisions for buyout options in case of a change of control or sale of the program.

The most recent analyst rating on (IRD) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Opus Genetics stock, see the IRD Stock Forecast page.

Spark’s Take on IRD Stock

According to Spark, TipRanks’ AI Analyst, IRD is a Neutral.

Opus Genetics faces significant financial challenges, with declining revenues and persistent losses undermining its financial stability. The technical indicators suggest a bearish trend, while the negative corporate event further highlights financing difficulties. These factors contribute to a low overall score, indicating a high-risk investment with uncertain prospects.

To see Spark’s full report on IRD stock, click here.

More about Opus Genetics

Opus Genetics, Inc. operates in the biotechnology industry, focusing on developing gene therapies to treat retinal degenerative diseases. The company is primarily engaged in creating treatments for conditions such as retinitis pigmentosa, with a market focus on genetic disorders affecting vision.

Average Trading Volume: 921,199

Technical Sentiment Signal: Strong Sell

Current Market Cap: $55.56M

See more insights into IRD stock on TipRanks’ Stock Analysis page.